News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
| Development capabilites |
|
We manage the development of our projects according to a matrix system which enables us an optimal allocation of our resources so each project can be handled in the best possible way. We have the expertise in preclinical and clinical trials, manufacturing, regulatory affairs, and innovative drug delivery and formulation.
|
|||||





